SCHEMBL10003404

SCHEMBL10003404

CCc1nc2c(cc1NC(=O)c1ccccc1)c(OCC(F)(F)F)c(C(=O)O)n2C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 0.40
▸ RAB9A P51151 3/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ MAPT P10636 3/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ HPGD P15428 3/20 0.38
▸ GAA P10253 2/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ ABL1 P00519 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ RIN1 Q13671 1/20 0.38
▸ SMO Q99835 1/20 0.37
▸ KCNK3 O14649 1/20 0.37
▸ KCNK9 Q9NPC2 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ AHR P35869 1/20 0.37
▸ UGCG Q16739 1/20 0.37
▸ PDE11A Q9HCR9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10004018 0.93 ALDH1A1 (0.41) RAB9ANPC1MAPTHPGDMEN1
SCHEMBL10003069 0.92 SMN1; SMN2 (0.41) RAB9ANPC1MAPTSMN1; SMN2MEN1
SCHEMBL10003167 0.92 F10 (0.40) RAB9AMAPTSMN1; SMN2HPGDGAA
SCHEMBL10003336 0.92 SMN1; SMN2 (0.41) HTTRAB9ANPC1MAPTSMN1; SMN2
SCHEMBL10003568 0.91 NPC1 (0.44) RAB9ANPC1MAPTSMN1; SMN2HPGD
SCHEMBL10003462 0.90 SMN1; SMN2 (0.47) RAB9ANPC1MAPTSMN1; SMN2HPGD
SCHEMBL10003839 0.90 MAPT (0.41) RAB9ANPC1MAPTSMN1; SMN2GAA
SCHEMBL10002857 0.89 L3MBTL1 (0.44) HPGDGAAMEN1KMT2AALDH1A1
SCHEMBL10003390 0.89 HTT (0.41) HTTRAB9ANPC1MAPTSMN1; SMN2
SCHEMBL10004202 0.89 ELANE (0.33) RAB9ANPC1MAPTHPGDSMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH HTT 3635/4885RAB9A 1389/4885NPC1 1300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback